Loading...

Dubinett Steven

TitleDirector
InstitutionUniversity of California Los Angeles
DepartmentCTSI
Address10833 Le Conte Ave.
CHS 37-131
Los Angeles CA 90095
Phone(310) 267-2725
vCardDownload vCard
    Other Positions
    TitleAssociate Vice Chancellor for Research

    TitleSenior Associate Dean Translational Research

    TitleProfessor

    TitleProfessor

    TitleChief

    TitleDivision Chief


    Collapse Research 
    Collapse Research Activities and Funding
    The Boston University-UCLA Lung Cancer Biomarker Development Lab
    NIH/NCI U01CA214182Sep 20, 2016 - Aug 31, 2021
    Role: Co-Principal Investigator
    UCLA Clinical Translational Science Institute
    NIH/NCATS UL1TR001881Jul 1, 2016 - May 31, 2021
    Role: Principal Investigator
    Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer
    NIH/NCI U01CA196408Sep 16, 2015 - Aug 31, 2020
    Role: Principal Investigator
    Clinically Actionable Neoantigens in Non-Small Cell Lung Cancer
    VA I01CX000345Apr 1, 2012 - Sep 30, 2021
    Role: Principal Investigator
    UCLA Clinical and Translational Science Institute
    NIH/NCRR KL2RR033185Jun 1, 2011 - Feb 29, 2016
    Role: Principal Investigator
    UCLA Clinical and Translational Science Institute
    NIH/NCATS KL2TR000122Jun 1, 2011 - Feb 29, 2016
    Role: Principal Investigator
    UCLA Clinical and Translational Science Institute
    NIH/NCRR TL1RR033175Jun 1, 2011 - Feb 29, 2016
    Role: Principal Investigator
    UCLA Clinical and Translational Science Institute
    NIH/NCATS TL1TR000121Jun 1, 2011 - Feb 29, 2016
    Role: Principal Investigator
    UCLA Clinical and Translational Science Institute
    NIH/NCRR UL1RR033176Jun 1, 2011 - Feb 29, 2016
    Role: Principal Investigator
    UCLA Clinical and Translational Science Institute
    NIH/NCATS UL1TR000124Jun 1, 2011 - Feb 29, 2016
    Role: Principal Investigator
    The UCLA - Boston University Lung Cancer Biomarker Development Laboratory
    NIH/NCI U01CA152751Sep 24, 2010 - Jun 30, 2016
    Role: Principal Investigator
    Cell Motility in the Pathogenesis of Lung Cancer
    VA I01BX000359Apr 1, 2009 - Sep 30, 2018
    Role: Principal Investigator
    Novel COX-2 and PGE2-dependent pathways in lung cancer
    NIH/NCI R01CA111851Mar 17, 2006 - Jan 31, 2013
    Role: Principal Investigator
    A Phase I Trial of CCL-21 Gene Modified DC in NSCLC
    NIH/NCI R21CA105705Sep 30, 2003 - May 31, 2010
    Role: Principal Investigator
    Pulmonary and Critical Care Medicine Training Program
    NIH/NHLBI T32HL072752Jul 1, 2003 - Apr 30, 2019
    Role: Principal Investigator
    UCLA SPORE IN LUNG CANCER
    NIH/NCI P50CA090388Jun 1, 2001 - Jun 30, 2010
    Role: Principal Investigator
    GENETIC IMMUNOTHERAPY FOR LUNG CANCER
    NIH/NCI R01CA085686Jan 1, 2001 - Dec 31, 2006
    Role: Principal Investigator
    FUNCTION AND REGULATION OF IL 10 IN LUNG CANCER
    NIH/NCI R01CA071818Apr 4, 1997 - Mar 31, 2002
    Role: Principal Investigator
    UCLA Tumor Immunology Training Program
    NIH/NCI T32CA009120Jul 1, 1980 - Mar 31, 2023
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Braas D, Go J, Graeber TG, Parlati F, Demo S, Li R, Walser TC, Gricowski M, Shuman R, Ibarra J, Fridman D, Phelps ME, Badran K, St John M, Bernthal NM, Federman N, Yanagawa J, Dubinett S, Sadeghi S, Christofk HR, Shackelford DB. The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. Cancer Cell. 2018 May 14; 33(5):905-921.e5. PMID: 29763624.
      View in: PubMed
    2. Salehi-Rad R, Dubinett S. Understanding the Hurdles in Lung Cancer Immunotherapy in the Context of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018 Mar 28. PMID: 29589957.
      View in: PubMed
    3. Pine PS, Lund SP, Parsons JR, Vang LK, Mahabal AA, Cinquini L, Kelly SC, Kincaid H, Crichton DJ, Spira A, Liu G, Gower AC, Pass HI, Goparaju C, Dubinett S, Krysan K, Stass SA, Kukuruga D, Van Keuren-Jensen K, Courtright-Lim A, Thompson KL, Rosenzweig BA, Sorbara L, Srivastava S, Salit ML. Summarizing performance for genome scale measurement of miRNA: reference samples and metrics. BMC Genomics. 2018 03 06; 19(1):180. PMID: 29510677.
      View in: PubMed
    4. Walser TC, Jing Z, Tran LM, Lin YQ, Yakobian N, Wang G, Krysan K, Zhu LX, Sharma S, Lee MH, Belperio JA, Ooi AT, Gomperts BN, Shay JW, Larsen JE, Minna JD, Hong LS, Fishbein MC, Dubinett S. Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res. 2018 Apr 15; 78(8):1986-1999. PMID: 29431637.
      View in: PubMed
    5. Dubinett S, Spira AE. Impact of Chronic Obstructive Pulmonary Disease on Immune-based Treatment for Lung Cancer. Moving toward Disease Interception. Am J Respir Crit Care Med. 2018 Feb 01; 197(3):278-280. PMID: 29072842.
      View in: PubMed
    6. Sivakumar S, Lucas FAS, McDowell TL, Lang W, Xu L, Fujimoto J, Zhang J, Futreal PA, Fukuoka J, Yatabe Y, Dubinett S, Spira AE, Fowler J, Hawk ET, Wistuba II, Scheet P, Kadara H. Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Res. 2017 11 15; 77(22):6119-6130. PMID: 28951454.
      View in: PubMed
    7. Pellionisz PA, Lin Y, Mallen-St Clair J, Luo J, Suwarnasarn A, Schaue D, Elashoff DA, Palma-Diaz F, Dubinett S, Sharma S, Wu B, St John MA. Use of a Novel Polymer in an Animal Model of Head and Neck Squamous Cell Carcinoma. Otolaryngol Head Neck Surg. 2018 Jan; 158(1):110-117. PMID: 28895464.
      View in: PubMed
    8. Pavel AB, Campbell JD, Liu G, Elashoff D, Dubinett S, Smith K, Whitney D, Lenburg ME, Spira A. Alterations in Bronchial Airway miRNA Expression for Lung Cancer Detection. Cancer Prev Res (Phila). 2017 Nov; 10(11):651-659. PMID: 28877936.
      View in: PubMed
    9. Pagano PC, Tran LM, Bendris N, O'Byrne S, Tse HT, Sharma S, Hoech JW, Park SJ, Liclican EL, Jing Z, Li R, Krysan K, Paul MK, Fontebasso Y, Larsen JE, Hakimi S, Seki A, Fishbein MC, Gimzewski JK, Carlo DD, Minna JD, Walser TC, Dubinett S. Identification of a Human Airway Epithelial Cell Subpopulation with Altered Biophysical, Molecular, and Metastatic Properties. Cancer Prev Res (Phila). 2017 Sep; 10(9):514-524. PMID: 28754664.
      View in: PubMed
    10. Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett S. Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clin Cancer Res. 2017 Aug 15; 23(16):4556-4568. PMID: 28468947.
      View in: PubMed
    11. Kang S, Li Q, Chen Q, Zhou Y, Park S, Lee G, Grimes B, Krysan K, Yu M, Wang W, Alber F, Sun F, Dubinett S, Li W, Zhou XJ. CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA. Genome Biol. 2017 03 24; 18(1):53. PMID: 28335812.
      View in: PubMed
    12. Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett S, Sadeghi S, Christofk HR, Shackelford DB. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. Cell Rep. 2017 01 17; 18(3):601-610. PMID: 28099841.
      View in: PubMed
    13. van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S. Assessing Researcher Needs for a Virtual Biobank. Biopreserv Biobank. 2017 Jun; 15(3):203-210. PMID: 27929677.
      View in: PubMed
    14. Arenberg D, Dubinett S. Lung Cancer: Evolving Concepts in Management. Semin Respir Crit Care Med. 2016 10; 37(5):647-648. PMID: 27732986.
      View in: PubMed
    15. Moses E, Wang T, Corbett S, Jackson GR, Drizik E, Perdomo C, Perdomo C, Kleerup E, Brooks D, O'Connor G, Dubinett S, Hayden P, Lenburg ME, Spira A. Molecular Impact of Electronic Cigarette Aerosol Exposure in Human Bronchial Epithelium. Toxicol Sci. 2017 01; 155(1):248-257. PMID: 27701119.
      View in: PubMed
    16. Lin Y, Mallen-St Clair J, Wang G, Luo J, Palma-Diaz F, Lai C, Elashoff DA, Sharma S, Dubinett S, St John M. p38 MAPK mediates epithelial-mesenchymal transition by regulating p38IP and Snail in head and neck squamous cell carcinoma. Oral Oncol. 2016 09; 60:81-9. PMID: 27531877.
      View in: PubMed
    17. Hong CS, Graham NA, Gu W, Espindola Camacho C, Mah V, Maresh EL, Alavi M, Bagryanova L, Krotee PAL, Gardner BK, Behbahan IS, Horvath S, Chia D, Mellinghoff IK, Hurvitz SA, Dubinett S, Critchlow SE, Kurdistani SK, Goodglick L, Braas D, Graeber TG, Christofk HR. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Rep. 2016 Feb 23; 14(7):1590-1601. PMID: 26876179; PMCID: PMC4816454.
    18. Momcilovic M, McMickle R, Abt E, Seki A, Simko SA, Magyar C, Stout DB, Fishbein MC, Walser TC, Dubinett S, Shackelford DB. Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers. Cancer Res. 2015 Nov 15; 75(22):4910-22. PMID: 26574479; PMCID: PMC4654699 [Available on 11/15/16].
    19. Lin Y, Mallen-St Clair J, Luo J, Sharma S, Dubinett S, St John M. p53 modulates NF-?B mediated epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol. 2015 Oct; 51(10):921-8. PMID: 26306422.
      View in: PubMed
    20. Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK, Milne GL, Figlin RA, Fishbein MC, Elashoff RM, Dubinett S. Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer. Cancer. 2015 Sep 15; 121(18):3298-306. PMID: 26033830; PMCID: PMC4864011.
    21. Zhu LX, Davoodi M, Srivastava MK, Kachroo P, Lee JM, St John M, Harris-White M, Huang M, Strieter RM, Dubinett S, Sharma S. GITR agonist enhances vaccination responses in lung cancer. Oncoimmunology. 2015 Apr; 4(4):e992237. PMID: 26137407.
      View in: PubMed
    22. Fontebasso Y, Dubinett S. Drug Development for Metastasis Prevention. Crit Rev Oncog. 2015; 20(5-6):449-73. PMID: 27279241.
      View in: PubMed
    23. Lee MH, Kachroo P, Pagano PC, Yanagawa J, Wang G, Walser TC, Krysan K, Sharma S, John MS, Dubinett S, Lee JM. Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway. J Cancer Sci Ther. 2014 Nov; 6(11):468-477. PMID: 26523208.
      View in: PubMed
    24. Liclican EL, Walser TC, Hazra S, Krysan K, Park SJ, Pagano PC, Gardner BK, Larsen JE, Minna JD, Dubinett S. Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy. Cancer Prev Res (Phila). 2014 Aug; 7(8):845-55. PMID: 24913817; PMCID: PMC4125465.
    25. Lin Y, Luo J, Zhu WE, Srivastava M, Schaue D, Elashoff DA, Dubinett S, Sharma S, Wu B, St John MA. A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model. Otolaryngol Head Neck Surg. 2014 Sep; 151(3):447-53. PMID: 24825873; PMCID: PMC4167678.
    26. Ooi AT, Gower AC, Zhang KX, Vick JL, Hong L, Nagao B, Wallace WD, Elashoff DA, Walser TC, Dubinett S, Pellegrini M, Lenburg ME, Spira A, Gomperts BN. Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res (Phila). 2014 May; 7(5):487-95. PMID: 24618292; PMCID: PMC4059064.
    27. Hanas JS, Peyton MD, Lerner MR, Lightfoot SA, Deb SJ, Hanas RJ, Vu NT, Kupiec TC, Stowell DE, Brackett DJ, Dubinett S, Hocker JR. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling. Cancer Invest. 2014 May; 32(4):136-43. PMID: 24579933.
      View in: PubMed
    28. Krysan K, Kusko R, Grogan T, O'Hearn J, Reckamp KL, Walser TC, Garon EB, Lenburg ME, Sharma S, Spira AE, Elashoff D, Dubinett S. PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. Mol Cancer Res. 2014 May; 12(5):765-74. PMID: 24469837; PMCID: PMC4020971.
    29. Garon EB, Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, Hong CS, Kamranpour N, Pitts S, Kabbinavar F, Patel C, von Euw E, Black A, Michelakis ED, Dubinett S, Slamon DJ. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2014 Mar; 140(3):443-52. PMID: 24442098; PMCID: PMC3939783.
    30. Kachroo P, Lee MH, Zhang L, Baratelli F, Lee G, Srivastava MK, Wang G, Walser TC, Krysan K, Sharma S, Dubinett S, Lee JM. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res. 2013 Nov 25; 32:97. PMID: 24274066; PMCID: PMC3906956.
    31. Grant JL, Fishbein MC, Hong LS, Krysan K, Minna JD, Shay JW, Walser TC, Dubinett S. A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis. Cancer Prev Res (Phila). 2014 Jan; 7(1):150-60. PMID: 24253315; PMCID: PMC3919444.
    32. Perdomo C, Campbell JD, Gerrein J, Tellez CS, Garrison CB, Walser TC, Drizik E, Si H, Gower AC, Vick J, Anderlind C, Jackson GR, Mankus C, Schembri F, O'Hara C, Gomperts BN, Dubinett S, Hayden P, Belinsky SA, Lenburg ME, Spira A. MicroRNA 4423 is a primate-specific regulator of airway epithelial cell differentiation and lung carcinogenesis. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):18946-51. PMID: 24158479; PMCID: PMC3839685.
    33. Ofili EO, Fair A, Norris K, Verbalis JG, Poland R, Bernard G, Stephens DS, Dubinett S, Imperato-McGinley J, Dottin RP, Pulley J, West A, Brown A, Mellman TA. Models of interinstitutional partnerships between research intensive universities and minority serving institutions (MSI) across the Clinical Translational Science Award (CTSA) consortium. Clin Transl Sci. 2013 Dec; 6(6):435-43. PMID: 24119157; PMCID: PMC4038384.
    34. Dubinett S, Spira A. Challenge and opportunity of targeted lung cancer chemoprevention. J Clin Oncol. 2013 Nov 20; 31(33):4169-71. PMID: 24002497.
      View in: PubMed
    35. Krysan K, Cui X, Gardner BK, Reckamp KL, Wang X, Hong L, Walser TC, Rodriguez NL, Pagano PC, Garon EB, Brothers JF, Elashoff D, Lee JM, Spira AE, Sharma S, Fishbein MC, Dubinett S. Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am J Transl Res. 2013; 5(5):481-96. PMID: 23977408; PMCID: PMC3745436.
    36. Liao W, Jordaan G, Srivastava MK, Dubinett S, Sharma S, Sharma S. Effect of epigenetic histone modifications on E-cadherin splicing and expression in lung cancer. Am J Cancer Res. 2013; 3(4):374-89. PMID: 23977447; PMCID: PMC3744017.
    37. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett S, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W. Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013 May 01; 19(9):2584-91. PMID: 23515407; PMCID: PMC3643999.
    38. Sharma S, Zhu L, Davoodi M, Harris-White M, Lee JM, St John M, Salgia R, Dubinett S. TLR3 agonists and proinflammatory antitumor activities. Expert Opin Ther Targets. 2013 May; 17(5):481-3. PMID: 23506058; PMCID: PMC3758767.
    39. Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, Jensen MR, Quadt C, Liu M, Dubinett S, Slamon DJ. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther. 2013 Jun; 12(6):890-900. PMID: 23493311; PMCID: PMC3681857.
    40. Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Márquez-Garbán DC, Desai AJ, Dering J, Hosmer W, von Euw EM, Dubinett S, Slamon DJ. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol. 2013 Mar; 8(3):270-8. PMID: 23399957; PMCID: PMC3573351.
    41. Sharma S, Zhu L, Srivastava MK, Harris-White M, Huang M, Lee JM, Rosen F, Lee G, Wang G, Kickhoefer V, Rome LH, Baratelli F, St John M, Reckamp K, Chul-Yang S, Hillinger S, Strieter R, Dubinett S. CCL21 Chemokine Therapy for Lung Cancer. Int Trends Immun. 2013 Jan; 1(1):10-15. PMID: 25264541.
      View in: PubMed
    42. Gomperts BN, Walser TC, Spira A, Dubinett S. Enriching the molecular definition of the airway "field of cancerization:" establishing new paradigms for the patient at risk for lung cancer. Cancer Prev Res (Phila). 2013 Jan; 6(1):4-7. PMID: 23233734; PMCID: PMC3717378.
    43. Srivastava MK, Dubinett S, Sharma S. Targeting MDSCs enhance therapeutic vaccination responses against lung cancer. Oncoimmunology. 2012 Dec 01; 1(9):1650-1651. PMID: 23264925.
      View in: PubMed
    44. Sharma S, Dubinett S, Salgia R. CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancer. Am J Respir Crit Care Med. 2012 Nov 15; 186(10):940-1. PMID: 23155211; PMCID: PMC4249776.
    45. Lu QY, Jin Y, Mao JT, Zhang ZF, Heber D, Dubinett S, Rao J. Green tea inhibits cycolooxygenase-2 in non-small cell lung cancer cells through the induction of Annexin-1. Biochem Biophys Res Commun. 2012 Nov 02; 427(4):725-30. PMID: 23036202; PMCID: PMC3490045.
    46. Srivastava MK, Zhu L, Harris-White M, Huang M, St John M, Lee JM, Salgia R, Cameron RB, Strieter R, Dubinett S, Sharma S. Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. Immunotargets Ther. 2012 Oct 01; 2012(1):7-12. PMID: 24791250.
      View in: PubMed
    47. Srivastava MK, Zhu L, Harris-White M, Kar UK, Kar U, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S, Sharma S. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One. 2012; 7(7):e40677. PMID: 22815789; PMCID: PMC3398024.
    48. Dennis M, Wang G, Luo J, Lin Y, Dohadwala M, Abemayor E, Elashoff DA, Sharma S, Dubinett S, St John MA. Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells. Otolaryngol Head Neck Surg. 2012 Oct; 147(4):726-32. PMID: 22568942; PMCID: PMC4167686.
    49. Hu D, Lau OD, Wang L, Wang G, Schaue D, Zhu L, Huang M, Lin Y, Dennis M, Abemayor E, Elashoff DA, Dubinett S, McBride WH, Sharma S, Wu B, St John MA. A novel modular polymer platform for the treatment of head and neck squamous cell carcinoma in an animal model. Arch Otolaryngol Head Neck Surg. 2012 Apr; 138(4):412-7. PMID: 22508626; PMCID: PMC4167672.
    50. Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS). Clin Transl Sci. 2012 Apr; 5(2):121-9. PMID: 22507116; PMCID: PMC3335735.
    51. Srivastava MK, Andersson Å, Zhu L, Harris-White M, Lee JM, Dubinett S, Sharma S. Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy. 2012 Mar; 4(3):291-304. PMID: 22401635; PMCID: PMC3324285.
    52. Huynh TP, Mah V, Sampson VB, Chia D, Fishbein MC, Horvath S, Alavi M, Wu DC, Harper J, Sarafian T, Dubinett S, Langhans SA, Goodglick L, Rajasekaran AK. Na,K-ATPase is a target of cigarette smoke and reduced expression predicts poor patient outcome of smokers with lung cancer. Am J Physiol Lung Cell Mol Physiol. 2012 Jun 01; 302(11):L1150-8. PMID: 22345575; PMCID: PMC3379038.
    53. Garon EB, Dubinett S. Mitotic inhibitors. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1791-2. PMID: 22005532; PMCID: PMC3812544.
    54. Heinrich EL, Walser TC, Krysan K, Liclican EL, Grant JL, Rodriguez NL, Dubinett S. The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis. Cancer Microenviron. 2012 Apr; 5(1):5-18. PMID: 21922183; PMCID: PMC3343201.
    55. Sharma S, Srivastava MK, Harris-White M, Lee JM, Dubinett S. MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancer. Expert Opin Biol Ther. 2011 Aug; 11(8):987-90. PMID: 21711210; PMCID: PMC3132083.
    56. Stoyanov E, Uddin M, Mankuta D, Dubinett S, Levi-Schaffer F. Mast cells and histamine enhance the proliferation of non-small cell lung cancer cells. Lung Cancer. 2012 Jan; 75(1):38-44. PMID: 21733595.
      View in: PubMed
    57. Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, Tashkin DP, Goodglick L, Holmes EC, Cameron RB, Dubinett S, Elashoff R, Szabo E, Elashoff D. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila). 2011 Jul; 4(7):984-93. PMID: 21733822; PMCID: PMC3153413.
    58. Andersson A, Srivastava MK, Harris-White M, Huang M, Zhu L, Elashoff D, Strieter RM, Dubinett S, Sharma S. Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer. Clin Cancer Res. 2011 Jun 01; 17(11):3660-72. PMID: 21636553; PMCID: PMC3118413.
    59. Al-Shyoukh I, Yu F, Feng J, Yan K, Dubinett S, Ho CM, Shamma JS, Sun R. Systematic quantitative characterization of cellular responses induced by multiple signals. BMC Syst Biol. 2011 May 30; 5:88. PMID: 21624115; PMCID: PMC3138445.
    60. Kar UK, Srivastava MK, Andersson A, Baratelli F, Huang M, Kickhoefer VA, Dubinett S, Rome LH, Sharma S. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS One. 2011 May 03; 6(5):e18758. PMID: 21559281; PMCID: PMC3086906.
    61. Gomperts BN, Spira A, Massion PP, Walser TC, Wistuba II, Minna JD, Dubinett S. Evolving concepts in lung carcinogenesis. Semin Respir Crit Care Med. 2011 Feb; 32(1):32-43. PMID: 21500122; PMCID: PMC3423907.
    62. Lee G, Gardner BK, Elashoff DA, Purcell CM, Sandha HS, Mao JT, Krysan K, Lee JM, Dubinett S. Elevated levels of CXC chemokine connective tissue activating peptide (CTAP)-III in lung cancer patients. Am J Transl Res. 2011 May 15; 3(3):226-33. PMID: 21654877; PMCID: PMC3102566.
    63. Mendelsohn AH, Lai CK, Shintaku IP, Fishbein MC, Brugman K, Elashoff DA, Abemayor E, Dubinett S, St John MA. Snail as a novel marker for regional metastasis in head and neck squamous cell carcinoma. Am J Otolaryngol. 2012 Jan-Feb; 33(1):6-13. PMID: 21439681.
      View in: PubMed
    64. Mortazavi F, Dubinett S, Rettig M. c-Crk proto-oncogene contributes to transcriptional repression of p120-catenin in non-small cell lung cancer cells. Clin Exp Metastasis. 2011 Apr; 28(4):391-404. PMID: 21336985; PMCID: PMC3081060.
    65. Hosmer WD, Dubinett S, Garon EB. Novel drugs--miscellaneous category. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S468-9. PMID: 21102242.
      View in: PubMed
    66. Garon EB, Dubinett S. Poly(ADP-ribose) polymerase inhibitors. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S455-6. PMID: 21102236.
      View in: PubMed
    67. Patz EF, Caporaso NE, Dubinett S, Massion PP, Hirsch FR, Minna JD, Gatsonis C, Duan F, Adams A, Apgar C, Medina RM, Aberle DR. National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers. J Thorac Oncol. 2010 Oct; 5(10):1502-6. PMID: 20871260; PMCID: PMC2963472.
    68. Mendelsohn AH, Lai CK, Shintaku IP, Elashoff DA, Dubinett S, Abemayor E, St John MA. Histopathologic findings of HPV and p16 positive HNSCC. Laryngoscope. 2010 Sep; 120(9):1788-94. PMID: 20803740.
      View in: PubMed
    69. Ooi AT, Mah V, Nickerson DW, Gilbert JL, Ha VL, Hegab AE, Horvath S, Alavi M, Maresh EL, Chia D, Gower AC, Lenburg ME, Spira A, Solis LM, Wistuba II, Walser TC, Wallace WD, Dubinett S, Goodglick L, Gomperts BN. Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. Cancer Res. 2010 Aug 15; 70(16):6639-48. PMID: 20710044; PMCID: PMC2924777.
    70. Dubinett S, Lee JM, Sharma S, Mulé JJ. Chemokines: can effector cells be redirected to the site of the tumor? Cancer J. 2010 Jul-Aug; 16(4):325-35. PMID: 20693843; PMCID: PMC3076643.
    71. Baratelli F, Lee JM, Hazra S, Lin Y, Walser TC, Schaue D, Pak PS, Elashoff D, Reckamp K, Zhang L, Fishbein MC, Sharma S, Dubinett S. PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res. 2010 Jun 30; 2(4):356-67. PMID: 20733946; PMCID: PMC2923860.
    72. Mortazavi F, An J, Dubinett S, Rettig M. p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells. Mol Cancer Res. 2010 May; 8(5):762-74. PMID: 20460685.
      View in: PubMed
    73. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett S, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT. Cancer and inflammation: promise for biologic therapy. J Immunother. 2010 May; 33(4):335-51. PMID: 20386472; PMCID: PMC2941912.
    74. Dohadwala M, Wang G, Heinrich E, Luo J, Lau O, Shih H, Munaim Q, Lee G, Hong L, Lai C, Abemayor E, Fishbein MC, Elashoff DA, Dubinett S, St John MA. The role of ZEB1 in the inflammation-induced promotion of EMT in HNSCC. Otolaryngol Head Neck Surg. 2010 May; 142(5):753-9. PMID: 20416468.
      View in: PubMed
    75. Gomperts BN, Spira A, Elashoff DE, Dubinett S. Lung cancer biomarkers: FISHing in the sputum for risk assessment and early detection. Cancer Prev Res (Phila). 2010 Apr; 3(4):420-3. PMID: 20332300.
      View in: PubMed
    76. Yanagawa J, Walser TC, Zhu LX, Hong L, Fishbein MC, Mah V, Chia D, Goodglick L, Elashoff DA, Luo J, Magyar CE, Dohadwala M, Lee JM, St John MA, Strieter RM, Sharma S, Dubinett S. Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clin Cancer Res. 2009 Nov 15; 15(22):6820-9. PMID: 19887480; PMCID: PMC2783274.
    77. Garon EB, Dubinett S. Intracellular signaling molecules. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1057-8. PMID: 19861915.
      View in: PubMed
    78. St John MA, Dohadwala M, Luo J, Wang G, Lee G, Shih H, Heinrich E, Krysan K, Walser T, Hazra S, Zhu L, Lai C, Abemayor E, Fishbein M, Elashoff DA, Sharma S, Dubinett S. Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma. Clin Cancer Res. 2009 Oct 01; 15(19):6018-27. PMID: 19789323; PMCID: PMC2782528.
    79. Lee WH, Hung MC, Iczkowski KA, Languino LR, Dubinett S, Wang D. The launch of the american journal of translational research. Am J Transl Res. 2009 Sep 01; 1(1):i. PMID: 19966932; PMCID: PMC2776285.
    80. Limsukon A, Susanto I, Soo Hoo GW, Dubinett S, Batra RK. Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy. Chest. 2009 Sep; 136(3):924-926. PMID: 19736197.
      View in: PubMed
    81. Dubinett S, Sharma S. Towards effective immunotherapy for lung cancer: simultaneous targeting of tumor-initiating cells and immune pathways in the tumor microenvironment. Immunotherapy. 2009 Sep; 1(5):721-5. PMID: 20636013.
      View in: PubMed
    82. Lee G, Walser TC, Dubinett S. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med. 2009 Jul; 15(4):303-7. PMID: 19417670.
      View in: PubMed
    83. Reckamp KL, Figlin RA, Burdick MD, Dubinett S, Elashoff RM, Strieter RM. CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer. 2009 Jun 29; 9:213. PMID: 19563666; PMCID: PMC2708193.
    84. Andersson A, Yang SC, Huang M, Zhu L, Kar UK, Batra RK, Elashoff D, Strieter RM, Dubinett S, Sharma S. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol. 2009 Jun 01; 182(11):6951-8. PMID: 19454692.
      View in: PubMed
    85. Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett S. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst. 2009 Apr 15; 101(8):554-9. PMID: 19351920; PMCID: PMC2669099.
    86. Lu QY, Yang Y, Jin YS, Zhang ZF, Heber D, Li FP, Dubinett S, Sondej MA, Loo JA, Rao JY. Effects of green tea extract on lung cancer A549 cells: proteomic identification of proteins associated with cell migration. Proteomics. 2009 Feb; 9(3):757-67. PMID: 19137550; PMCID: PMC2775082.
    87. Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G, Sharma S, Dubinett S. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc. 2008 Dec 01; 5(8):811-5. PMID: 19017734; PMCID: PMC4080902.
    88. Dubinett S, Aberle DR, Tashkin DP, Mao JT. The partners--airflow obstruction, emphysema, and lung cancer. Am J Respir Crit Care Med. 2008 Oct 01; 178(7):665-6. PMID: 18796652.
      View in: PubMed
    89. Dubinett S, Mao JT, Hazra S. Focusing downstream in lung cancer prevention: 15-hydroxyprostaglandin dehydrogenase. Cancer Prev Res (Phila). 2008 Sep; 1(4):223-5. PMID: 19138963.
      View in: PubMed
    90. Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto PS, Zeng G, Batra RK, Sharma S, Dubinett S, Lee JM. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J Transl Med. 2008 Jul 22; 6:38. PMID: 18644162; PMCID: PMC2507704.
    91. Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett S, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol. 2008 May; 3(5):545-55. PMID: 18449013; PMCID: PMC3374724.
    92. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett S. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol. 2008 Jun; 66(3):208-17. PMID: 18304833; PMCID: PMC2483429.
    93. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, Hsu YT, Dubinett S, Phelps ME, Czernin J, Weber WA. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging. 2008 Jun; 35(6):1089-99. PMID: 18239919.
      View in: PubMed
    94. Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, St John M, Sharma S, Dubinett S. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol. 2008 Feb; 3(2):107-10. PMID: 18303428.
      View in: PubMed
    95. Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett S. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol. 2008 Feb; 3(2):117-24. PMID: 18303430.
      View in: PubMed
    96. Hazra S, Peebles KA, Sharma S, Mao JT, Dubinett S. The Role of PPARgamma in the Cyclooxygenase Pathway in Lung Cancer. PPAR Res. 2008; 2008:790568. PMID: 18769553; PMCID: PMC2526169.
    97. Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, Baratelli FE, Garon E, Sharma S, Dubinett S. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther. 2007 Oct; 7(10):1405-21. PMID: 17944566.
      View in: PubMed
    98. Hazra S, Dubinett S. Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells. Prostaglandins Leukot Essent Fatty Acids. 2007 Jul; 77(1):51-8. PMID: 17697767; PMCID: PMC2045645.
    99. Liu M, Yang SC, Sharma S, Luo J, Cui X, Peebles KA, Huang M, Sato M, Ramirez RD, Shay JW, Minna JD, Dubinett S. EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells. Am J Respir Cell Mol Biol. 2007 Nov; 37(5):578-88. PMID: 17600311; PMCID: PMC2048680.
    100. Hazra S, Batra RK, Tai HH, Sharma S, Cui X, Dubinett S. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol. 2007 Jun; 71(6):1715-20. PMID: 17412838.
      View in: PubMed
    101. Lee JM, Mao JT, Krysan K, Dubinett S. Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC. Future Oncol. 2007 Apr; 3(2):149-53. PMID: 17381414.
      View in: PubMed
    102. Lu QY, Jin YS, Zhang ZF, Le AD, Heber D, Li FP, Dubinett S, Rao JY. Green tea induces annexin-I expression in human lung adenocarcinoma A549 cells: involvement of annexin-I in actin remodeling. Lab Invest. 2007 May; 87(5):456-65. PMID: 17351649.
      View in: PubMed
    103. Feeley BT, Liu NQ, Conduah AH, Krenek L, Roth K, Dougall WC, Huard J, Dubinett S, Lieberman JR. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res. 2006 Oct; 21(10):1571-80. PMID: 16995812.
      View in: PubMed
    104. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006 Oct 01; 12(19):5659-67. PMID: 17020967.
      View in: PubMed
    105. Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y, Rao J, Li W, Chen D, Langford MP, Duggan C, Belldegrun AS, Dubinett S. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol. 2006 Sep 15; 177(6):3582-9. PMID: 16951317.
      View in: PubMed
    106. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett S, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15; 12(12):3661-97. PMID: 16778094.
      View in: PubMed
    107. Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett S, Figlin RA. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 1):3381-8. PMID: 16740761.
      View in: PubMed
    108. Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC, Hong L, Lai C, Cameron RB, Gemmill RM, Drabkin HA, Dubinett S. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. 2006 May 15; 66(10):5338-45. PMID: 16707460.
      View in: PubMed
    109. Krysan K, Reckamp KL, Sharma S, Dubinett S. The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem. 2006 May; 6(3):209-20. PMID: 16712449.
      View in: PubMed
    110. Cui X, Yang SC, Sharma S, Heuze-Vourc'h N, Dubinett S. IL-4 regulates COX-2 and PGE2 production in human non-small cell lung cancer. Biochem Biophys Res Commun. 2006 May 19; 343(4):995-1001. PMID: 16574063.
      View in: PubMed
    111. Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett S, Sharma S. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2006 Mar 15; 66(6):3205-13. PMID: 16540672.
      View in: PubMed
    112. Hoang B, Zhu L, Shi Y, Frost P, Yan H, Sharma S, Sharma S, Goodglick L, Dubinett S, Lichtenstein A. Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood. 2006 Jun 01; 107(11):4484-90. PMID: 16497971; PMCID: PMC1895799.
    113. Pan J, Burdick MD, Belperio JA, Xue YY, Gerard C, Sharma S, Dubinett S, Strieter RM. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol. 2006 Feb 01; 176(3):1456-64. PMID: 16424173.
      View in: PubMed
    114. Mao JT, Fishbein MC, Adams B, Roth MD, Goodglick L, Hong L, Burdick M, Strieter ER, Holmes C, Tashkin DP, Dubinett S. Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res. 2006 Jan 01; 12(1):314-20. PMID: 16397057.
      View in: PubMed
    115. Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Garban HJ, Dubinett S, Pietras RJ. Aromatase inhibitors in human lung cancer therapy. Cancer Res. 2005 Dec 15; 65(24):11287-91. PMID: 16357134.
      View in: PubMed
    116. Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res. 2005 Nov 01; 11(21):7674-82. PMID: 16278387.
      View in: PubMed
    117. Liu W, Dubinett S, Patterson SL, Kelly KA. COX-2 inhibition affects growth rate of Chlamydia muridarum within epithelial cells. Microbes Infect. 2006 Feb; 8(2):478-86. PMID: 16297651.
      View in: PubMed
    118. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett S, Zabaleta J, Ochoa JB, Gilbert J, Ochoa AC. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005 Oct 03; 202(7):931-9. PMID: 16186186; PMCID: PMC2213169.
    119. Baratelli F, Lin Y, Zhu L, Yang SC, Heuzé-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubinett S. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol. 2005 Aug 01; 175(3):1483-90. PMID: 16034085.
      View in: PubMed
    120. Heuzé-Vourc'h N, Liu M, Dalwadi H, Baratelli FE, Zhu L, Goodglick L, Põld M, Sharma S, Ramirez RD, Shay JW, Minna JD, Strieter RM, Dubinett S. IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression. Biochem Biophys Res Commun. 2005 Jul 29; 333(2):470-5. PMID: 15950941.
      View in: PubMed
    121. Sharma S, Zhu L, Yang SC, Zhang L, Lin J, Hillinger S, Gardner B, Reckamp K, Strieter RM, Huang M, Batra RK, Dubinett S. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol. 2005 Jul 15; 175(2):813-9. PMID: 16002678.
      View in: PubMed
    122. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, Dubinett S. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 2005 Jul 15; 65(14):6275-81. PMID: 16024629.
      View in: PubMed
    123. Mao JT, Cui X, Reckamp K, Liu M, Krysan K, Dalwadi H, Sharma S, Hazra S, Strieter R, Gardner B, Dubinett S. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer. 2005 Jul; 7(1):30-9. PMID: 16098242.
      View in: PubMed
    124. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett S. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005 Jun 15; 65(12):5211-20. PMID: 15958566.
      View in: PubMed
    125. Baratelli F, Krysan K, Heuzé-Vourc'h N, Zhu L, Escuadro B, Sharma S, Reckamp K, Dohadwala M, Dubinett S. PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. J Leukoc Biol. 2005 Aug; 78(2):555-64. PMID: 15908458.
      View in: PubMed
    126. Zeng G, Aldridge ME, Wang Y, Pantuck AJ, Wang AY, Liu YX, Han Y, Yuan YH, Robbins PF, Dubinett S, deKernion JB, Belldegrun AS. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer. 2005 Mar 20; 114(2):268-73. PMID: 15540228.
      View in: PubMed
    127. Gamradt SC, Feeley BT, Liu NQ, Roostaeian J, Lin YQ, Zhu LX, Sharma S, Dubinett S, Lieberman JR. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone. Anticancer Res. 2005 Jan-Feb; 25(1A):107-15. PMID: 15816526.
      View in: PubMed
    128. Strieter RM, Belperio JA, Burdick MD, Sharma S, Dubinett S, Keane MP. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann N Y Acad Sci. 2004 Dec; 1028:351-60. PMID: 15650260.
      View in: PubMed
    129. Baratelli FE, Heuzé-Vourc'h N, Krysan K, Dohadwala M, Riedl K, Sharma S, Dubinett S. Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix. J Immunol. 2004 Nov 01; 173(9):5458-66. PMID: 15494493.
      View in: PubMed
    130. Mao JT, Tsu IH, Dubinett S, Adams B, Sarafian T, Baratelli F, Roth MD, Serio KJ. Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide. Clin Cancer Res. 2004 Oct 15; 10(20):6872-8. PMID: 15501964.
      View in: PubMed
    131. Põld M, Krysan K, Põld A, Dohadwala M, Heuze-Vourc'h N, Mao JT, Riedl KL, Sharma S, Dubinett S. Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. Cancer Res. 2004 Sep 15; 64(18):6549-55. PMID: 15374967.
      View in: PubMed
    132. Krysan K, Dalwadi H, Sharma S, Põld M, Dubinett S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res. 2004 Sep 15; 64(18):6359-62. PMID: 15374938.
      View in: PubMed
    133. Dubinett S, Elashoff D, Meyerson M. Assessing prognosis in non-small-cell lung cancer: avenues to a more complete picture? J Clin Oncol. 2004 Aug 15; 22(16):3209-11. PMID: 15249586.
      View in: PubMed
    134. Riedl K, Krysan K, Põld M, Dalwadi H, Heuze-Vourc'h N, Dohadwala M, Liu M, Cui X, Figlin R, Mao JT, Strieter R, Sharma S, Dubinett S. Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat. 2004 Jun; 7(3):169-84. PMID: 15296859.
      View in: PubMed
    135. Zhang L, Keane MP, Zhu LX, Sharma S, Rozengurt E, Strieter RM, Dubinett S, Huang M. Interleukin-7 and transforming growth factor-beta play counter-regulatory roles in protein kinase C-delta-dependent control of fibroblast collagen synthesis in pulmonary fibrosis. J Biol Chem. 2004 Jul 02; 279(27):28315-9. PMID: 15133032.
      View in: PubMed
    136. Krysan K, Dohadwala M, Luo J, Lin Y, Zhu L, Heuze-Vourc'h N, Goodglick L, Merchant F, Seligson D, Pold M, Strieter R, Sharma S, Dubinett S. Cyclooxygenase-2-dependent expression of survivin in non-small cell lung cancer. Chest. 2004 May; 125(5 Suppl):140S. PMID: 15136466.
      View in: PubMed
    137. Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, Strieter RM, Dubinett S, Sharma S. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res. 2004 Apr 15; 10(8):2891-901. PMID: 15102698.
      View in: PubMed
    138. Sandler AB, Dubinett S. COX-2 inhibition and lung cancer. Semin Oncol. 2004 Apr; 31(2 Suppl 7):45-52. PMID: 15179623.
      View in: PubMed
    139. Põld M, Zhu LX, Sharma S, Burdick MD, Lin Y, Lee PP, Põld A, Luo J, Krysan K, Dohadwala M, Mao JT, Batra RK, Strieter RM, Dubinett S. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res. 2004 Mar 01; 64(5):1853-60. PMID: 14996749.
      View in: PubMed
    140. Gardner B, Zhu LX, Roth MD, Tashkin DP, Dubinett S, Sharma S. Cocaine modulates cytokine and enhances tumor growth through sigma receptors. J Neuroimmunol. 2004 Feb; 147(1-2):95-8. PMID: 14741436.
      View in: PubMed
    141. Hillinger S, Yang SC, Zhu L, Huang M, Duckett R, Atianzar K, Batra RK, Strieter RM, Dubinett S, Sharma S. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J Immunol. 2003 Dec 15; 171(12):6457-65. PMID: 14662845.
      View in: PubMed
    142. Mao JT, Roth MD, Serio KJ, Baratelli F, Zhu L, Holmes EC, Strieter RM, Dubinett S. Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5835-41. PMID: 14676104.
      View in: PubMed
    143. Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Põld M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S, Dubinett S. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J. 2004 Jan; 18(1):206-8. PMID: 14597555.
      View in: PubMed
    144. Riedl K, Baratelli F, Batra RK, Yang SC, Luo J, Escuadro B, Figlin R, Strieter R, Sharma S, Dubinett S. Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer. 2003 Nov 02; 2:35. PMID: 14613584; PMCID: PMC270078.
    145. Sharma S, Batra RK, Yang SC, Hillinger S, Zhu L, Atianzar K, Strieter RM, Riedl K, Huang M, Dubinett S. Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Hum Gene Ther. 2003 Nov 01; 14(16):1511-24. PMID: 14577913; PMCID: PMC1471881.
    146. Gardner B, Zhu LX, Sharma S, Tashkin DP, Dubinett S. Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J. 2003 Nov; 17(14):2157-9. PMID: 12958151.
      View in: PubMed
    147. Zhang L, Sharma S, Zhu LX, Kogai T, Hershman JM, Brent GA, Dubinett S, Huang M. Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer cells. Cancer Res. 2003 Aug 15; 63(16):5065-72. PMID: 12941836.
      View in: PubMed
    148. Sharma S, Yang SC, Hillinger S, Zhu LX, Huang M, Batra RK, Lin JF, Burdick MD, Strieter RM, Dubinett S. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10. Mol Cancer. 2003 Apr 15; 2:22. PMID: 12740040; PMCID: PMC155639.
    149. Zhu LX, Sharma S, Gardner B, Escuadro B, Atianzar K, Tashkin DP, Dubinett S. IL-10 mediates sigma 1 receptor-dependent suppression of antitumor immunity. J Immunol. 2003 Apr 01; 170(7):3585-91. PMID: 12646621.
      View in: PubMed
    150. Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Atianzar K, Luo J, Zhu L, Lin Y, Huang M, Dohadwala M, Batra RK, Dubinett S. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res. 2003 Mar; 9(3):961-8. PMID: 12631593.
      View in: PubMed
    151. Heuze-Vourc'h N, Zhu L, Krysan K, Batra RK, Sharma S, Dubinett S. Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells. Cancer Res. 2003 Feb 15; 63(4):766-70. PMID: 12591723.
      View in: PubMed
    152. Batra RK, Lin Y, Sharma S, Dohadwala M, Luo J, Pold M, Dubinett S. Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I kappa B kinase-dependent mechanism. Cancer Res. 2003 Feb 01; 63(3):642-6. PMID: 12566308.
      View in: PubMed
    153. Sharma S, Yang SC, Batra RK, Dubinett S. Intratumoral therapy with cytokine gene-modified dendritic cells in murine lung cancer models. Methods Mol Med. 2003; 75:711-22. PMID: 12407774.
      View in: PubMed
    154. Dubinett S, Sharma S, Huang M, Dohadwala M, Pold M, Mao JT. Cyclooxygenase-2 in lung cancer. Prog Exp Tumor Res. 2003; 37:138-62. PMID: 12795053.
      View in: PubMed
    155. Sharma S, Huang M, Dohadwala M, Pold M, Batra RK, Dubinett S. Cyclooxygenase 2-dependent regulation of antitumor immunity in lung cancer. Methods Mol Med. 2003; 75:723-36. PMID: 12407775.
      View in: PubMed
    156. Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol. 2002 Nov; 42(11 Suppl):71S-81S. PMID: 12412839.
      View in: PubMed
    157. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S, Dubinett S. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem. 2002 Dec 27; 277(52):50828-33. PMID: 12393872; PMCID: PMC1471886.
    158. Bernal RM, Sharma S, Gardner BK, Douglas JT, Bergelson JM, Dubinett S, Batra RK. Soluble coxsackievirus adenovirus receptor is a putative inhibitor of adenoviral gene transfer in the tumor milieu. Clin Cancer Res. 2002 Jun; 8(6):1915-23. PMID: 12060636.
      View in: PubMed
    159. Basak SK, Harui A, Stolina M, Sharma S, Mitani K, Dubinett S, Roth MD. Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood. 2002 Apr 15; 99(8):2869-79. PMID: 11929777.
      View in: PubMed
    160. Huang M, Sharma S, Zhu LX, Keane MP, Luo J, Zhang L, Burdick MD, Lin YQ, Dohadwala M, Gardner B, Batra RK, Strieter RM, Dubinett S. IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. J Clin Invest. 2002 Apr; 109(7):931-7. PMID: 11927620; PMCID: PMC150933.
    161. Gardner B, Zu LX, Sharma S, Liu Q, Makriyannis A, Tashkin DP, Dubinett S. Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. Biochem Biophys Res Commun. 2002 Jan 11; 290(1):91-6. PMID: 11779138.
      View in: PubMed